CorMedix Shares Rise 21% After Preliminary 4Q Results Beat Estimates

Dow Jones

Jan 07, 2025

By Kailyn Rhone

Shares of CorMedix were higher after the company reported preliminary fourth-quarter results that beat the company's and analysts' expectations.

The company's stock increased 21% to $9.63 in morning trading Tuesday. For the year, shares are up 23%.

CorMedix said it is shipping DefenCath, its tool to reduce the incidence of catheter-related bloodstream infections, to all three of its mid-sized dialysis operator customers and has seen continuous ordering of increasing sizes throughout the quarter.

The Berkeley Heights, N.J.-based pharmaceutical company also announced a deal with Syneos Health for inpatient expansion and to reinforce its commitment to grow DefenCath across settings of care.

The company said Tuesday that it sees fourth-quarter revenue of $31 million, surpassing analysts' expectations of $19.7 million, according to FactSet.

CorMedix also sees full-year sales of around $43 million, beating the $32 million analysts polled by FactSet expected.

The company's preliminary results surpassed its guidance of becoming breakeven by year-end, said Chief Executive Joe Todisco.

"I believe we begin 2025 in a strong position," Todisco said.

Write to Kailyn Rhone at kailyn.rhone@wsj.com

(END) Dow Jones Newswires

January 07, 2025 10:37 ET (15:37 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2501865897"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2501865897\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2501865897?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-07 23:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501865897","market":"hk","top_or_hot":-1,"title":"CorMedix Shares Rise 21% After Preliminary 4Q Results Beat Estimates","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kailyn Rhone \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of CorMedix were higher after the company reported preliminary fourth-quarter results that beat the company's and analysts' expectations. \n</p>\n<p>\n  The company's stock increased 21% to $9.63 in morning trading Tuesday. For the year, shares are up 23%. \n</p>\n<p>\n  CorMedix said it is shipping DefenCath, its tool to reduce the incidence of catheter-related bloodstream infections, to all three of its mid-sized dialysis operator customers and has seen continuous ordering of increasing sizes throughout the quarter. \n</p>\n<p>\n  The Berkeley Heights, N.J.-based pharmaceutical company also announced a deal with Syneos Health for inpatient expansion and to reinforce its commitment to grow DefenCath across settings of care. \n</p>\n<p>\n  The company said Tuesday that it sees fourth-quarter revenue of $31 million, surpassing analysts' expectations of $19.7 million, according to FactSet. \n</p>\n<p>\n  CorMedix also sees full-year sales of around $43 million, beating the $32 million analysts polled by FactSet expected. \n</p>\n<p>\n  The company's preliminary results surpassed its guidance of becoming breakeven by year-end, said Chief Executive Joe Todisco. \n</p>\n<p>\n  \"I believe we begin 2025 in a strong position,\" Todisco said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kailyn Rhone at kailyn.rhone@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 07, 2025 10:37 ET (15:37 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CorMedix Shares Rise 21% After Preliminary 4Q Results Beat Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorMedix Shares Rise 21% After Preliminary 4Q Results Beat Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-07 23:37</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kailyn Rhone \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of CorMedix were higher after the company reported preliminary fourth-quarter results that beat the company's and analysts' expectations. \n</p>\n<p>\n  The company's stock increased 21% to $9.63 in morning trading Tuesday. For the year, shares are up 23%. \n</p>\n<p>\n  CorMedix said it is shipping DefenCath, its tool to reduce the incidence of catheter-related bloodstream infections, to all three of its mid-sized dialysis operator customers and has seen continuous ordering of increasing sizes throughout the quarter. \n</p>\n<p>\n  The Berkeley Heights, N.J.-based pharmaceutical company also announced a deal with Syneos Health for inpatient expansion and to reinforce its commitment to grow DefenCath across settings of care. \n</p>\n<p>\n  The company said Tuesday that it sees fourth-quarter revenue of $31 million, surpassing analysts' expectations of $19.7 million, according to FactSet. \n</p>\n<p>\n  CorMedix also sees full-year sales of around $43 million, beating the $32 million analysts polled by FactSet expected. \n</p>\n<p>\n  The company's preliminary results surpassed its guidance of becoming breakeven by year-end, said Chief Executive Joe Todisco. \n</p>\n<p>\n  \"I believe we begin 2025 in a strong position,\" Todisco said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kailyn Rhone at kailyn.rhone@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 07, 2025 10:37 ET (15:37 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRMD","symbol_name":"CorMedix Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2501865897","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501865897","pubTimestamp":1736264220,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of CorMedix were higher after the company reported preliminary fourth-quarter results that beat the company's and analysts' expectations.The company's stock increased 21% to $9.63 in morning trading Tuesday. For the year, shares are up 23%.CorMedix said it is shipping DefenCath, its tool to reduce the incidence of catheter-related bloodstream infections, to all three of its mid-sized dialysis operator customers and has seen continuous ordering of increasing sizes throughout the quarter.The Berkeley Heights, N.J.-based pharmaceutical company also announced a deal with Syneos Health for inpatient expansion and to reinforce its commitment to grow DefenCath across settings of care.The company said Tuesday that it sees fourth-quarter revenue of $31 million, surpassing analysts' expectations of $19.7 million, according to FactSet.CorMedix also sees full-year sales of around $43 million, beating the $32 million analysts polled by FactSet expected.The company's preliminary results surpa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRMD":"CorMedix Inc.","BK4007":"制药"},"translate_title":"第四季度初步业绩超出预期后，CorMedix股价上涨21%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRMD":0.9},"content_text":"By Kailyn Rhone \n\n\n \n\n\n  Shares of CorMedix were higher after the company reported preliminary fourth-quarter results that beat the company's and analysts' expectations. \n\n\n  The company's stock increased 21% to $9.63 in morning trading Tuesday. For the year, shares are up 23%. \n\n\n  CorMedix said it is shipping DefenCath, its tool to reduce the incidence of catheter-related bloodstream infections, to all three of its mid-sized dialysis operator customers and has seen continuous ordering of increasing sizes throughout the quarter. \n\n\n  The Berkeley Heights, N.J.-based pharmaceutical company also announced a deal with Syneos Health for inpatient expansion and to reinforce its commitment to grow DefenCath across settings of care. \n\n\n  The company said Tuesday that it sees fourth-quarter revenue of $31 million, surpassing analysts' expectations of $19.7 million, according to FactSet. \n\n\n  CorMedix also sees full-year sales of around $43 million, beating the $32 million analysts polled by FactSet expected. \n\n\n  The company's preliminary results surpassed its guidance of becoming breakeven by year-end, said Chief Executive Joe Todisco. \n\n\n  \"I believe we begin 2025 in a strong position,\" Todisco said. \n\n\n \n\n\n  Write to Kailyn Rhone at kailyn.rhone@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 07, 2025 10:37 ET (15:37 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}